相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Switch from Enfuvirtide to Raltegravir in Virologically Suppressed Multidrug-Resistant HIV-1-Infected Patients: A Randomized Open-Label Trial
Nathalie De Castro et al.
CLINICAL INFECTIOUS DISEASES (2009)
Raltegravir: The First HIV Integrase Inhibitor
Jennifer Cocohoba et al.
CLINICAL THERAPEUTICS (2008)
Antiretroviral treatment of adult HIV infection - 2008 recommendations of the International AIDS Society USA panel
Scott M. Hammer et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection
David A. Cooper et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Raltegravir with optimized background therapy for resistant HIV-1 infection
Roy T. Steigbigel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial
Vincent Soriano et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2008)
Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels - Results of a prospective randomized trial (AIDS clinical trial group 5725s)
Pablo Tebas et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2007)
Class of antiretroviral drugs and the risk of myocardial infarction
Nina Friis-Moller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Sustained improvement of dyslipidaemia in HAART-treated patients replacing stavudine with tenofovir
Josep M. Llibre et al.
AIDS (2006)
Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy:: Recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group
MP Dubé et al.
CLINICAL INFECTIOUS DISEASES (2003)
Cardiovascular disease risk factors in HIV patients -: association with antiretroviral therapy.: Results from the DAD study
N Friis-Moller et al.
AIDS (2003)
Human immunodeficiency virus type 1 genotypic and pharmacokinetic, determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients
B Masquelier et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
Replacing ritonavir by nelfinavir or nelfinavir/saquinavir as part of highly active antiretroviral therapy leads to an improvement of triglyceride levels
AMJ Wensing et al.
AIDS (2001)
Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients
DJ Kempf et al.
JOURNAL OF VIROLOGY (2001)
分享论文
